Inhibitors of human EZH2, and methods of use thereof
The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.
1. A method for treating cancer or myelodysplastic syndromes (MDS) in a subject having a Enhancer of Zeste Homolog 2 (EZH2) mutation in the substrate pocket domain of SEQ ID NO: 6, wherein SEQ ID NO: 6 comprises a mutation at amino acid position Y641 of EZH2 of SEQ ID NO: 1, wherein the mutation at amino acid position Y641 is selected from the group consisting of a substitution of phenylalanine (F) for the wild type residue tyrosine (Y) at amino acid position 641 of SEQ ID NO: 1 (Y641 F); a substitution of histidine (H) for the wild type residue tyrosine (Y) at amino acid position 641 of SEQ ID NO: 1 (Y641 H); a substitution of asparagine (N) for the wild type residue tyrosine (Y) at amino acid position 641 of SEQ ID NO: 1 (Y641 N); and a substitution of serine (S) for the wild type residue tyrosine (Y) at amino acid position 641 of SEQ ID NO: 1 (Y641 S); comprising administering to said subject a therapeutically effective amount of an EZH2 inhibitor, wherein the EZH2 inhibitor is
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the EZH2 mutation increases EZH2 trimethylation of Lys27 of histone H3 (H3-K27).
3. A method for treating cancer or myelodysplastic syndromes (MDS) in a subject having an increased level of trimethylated H3-K27 as a result of an EZH2 mutation in the substrate pocket domain of SEQ ID NO: 6, wherein SEQ ID NO: 6 comprises a mutation at amino acid position Y641 of EZH2 of SEQ ID NO: 1, wherein the mutation at amino acid position Y641 is selected from the group consisting of a substitution of phenylalanine (F) for the wild type residue tyrosine (Y) at amino acid position 641 of SEQ ID NO: 1 (Y641 F); a substitution of histidine (H) for the wild type residue tyrosine (Y) at amino acid position 641 of SEQ ID NO: 1 (Y641 H); a substitution of asparagine (N) for the wild type residue tyrosine (Y) at amino acid position 641 of SEQ ID NO: 1 (Y641 N); and a substitution of serine (S) for the wild type residue tyrosine (Y) at amino acid position 641 of SEQ ID NO: 1 (Y641 S); comprising administering to said subject a therapeutically effective amount of an EZH2 inhibitor, wherein the EZH2 inhibitor is
or a pharmaceutically acceptable salt thereof.
4. The method of claim 1 or 3 , wherein the EZH2 inhibitor inhibits the conversion of H3K27 to trimethylated H3-K27.
5. The method of claim 1 or 3 , wherein administration of the EZH2 inhibitor treats or alleviates a symptom of the cancer or MDS in the subject.
6. The method of claim 1 or 3 , wherein the EZH2 mutation is a EZH2 polypeptide mutation or a nucleic acid sequence mutation encoding a mutant EZH2 polypeptide.
7. The method of claim 1 or 3 , wherein the cancer is lymphoma.
8. The method of claim 7 , wherein the lymphoma is selected from the group consisting of non-Hodgkin lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma.